Why Should I Go With Organic Skin Care?

You might be asking yourself why the movement towards organic skin care products has been so enforced within the past few years. If you are asking yourself this, you may want to try it. Those who have turned to organic skin care have discovered a refreshing secret that has given them solutions to the many ailments found in today’s world. By applying the organic ingredients, the skin receives the strength and treatment it needs to defend against many attacking and irritating conditions. With strengthened skin, you can be sure to feel a new youth and vigor that is noticeable to your peers.

What can be considered organic? If it isn’t straight from the plant that naturally produces the ingredient, it cannot be organic. Even the plant itself must be grown in an environment that has not been chemically influenced. This is to avoid the taint of human interference in the growth of the plant. Any organic ingredient cannot contain debilitating substances. Chemicals, petroleum and other by-products are some such substances. Organic ingredients are considered pure without human engineering involved in the growth of the plant.

Without the involvement of bioengineering or chemical influence, these ingredients are safe to apply to the skin. There is no harmful substance that will penetrate the skin, and you will notice the change. The recuperating process that the skin does so well will be enhanced to its greatest potential.

The consequences of using products that contain either bioengineered or even entirely synthetic ingredients can eventually be detrimental to the skin. Applications that ought to help improve your skin will eventually come to harm you after a period of time. The chemicals will enter the body and can alter your bodily systems. Using synthesized products may harm your body’s ability to fight illness or give adequate oxygen to all parts of the body.

Now if we track the process of acquiring the ingredients, we find that only the highest of quality is used in these products. From all parts of the world, diverse cultures have gradually joined in helping supply these materials. Since the focus is not mass production, each farmer and caretaker is graceful in its nurturing of the plants that will be used. It is for this reason that the ingredients are hard to come by at this point in time. Lack of cooperation from farming communities has made large production of organic substances impossible at this time.

While the organic market is growing rapidly, it maintains its standards of quality, and each product guarantees the satisfaction of its users. The use of organic care materials will continue to enhance your lifestyle, and give you another reason to smile.

Rice University – Medical Center Apartments

William Marsh Rice University (commonly known as Rice University) is a private research university located in Houston, Texas, United States. The campus is located near the Houston Museum District and adjacent to the Texas Medical Center.

Rice enrolled 3,001 undergraduate, 897 post-graduate, and 1,247 doctoral students and awarded 1,448 degrees in 2007. The university is organized into eight schools offering 40 undergraduate degree programs, 51 masters programs, and 29 doctoral programs.

Rice is noted for its applied science programs in the fields of nanotechnology, artificial heart research, structural chemical analysis, and space science.

Smalley Institute for Nanoscale Science and Technology (SINST)  – the nation’s first nanotechnology center Center for Biological and Environmental Nanotechnology (CBEN – promotes the discovery and development of nanomaterials that enable new medical and environmental technologies Laboratory for Nanophotonics (LANP) – provides a resource for education and research breakthroughs and advances in the broad, multidisciplinary field of nanophotonics Rice Quantum Institute – organization dedicated to research and higher education in areas relating to quantum phenomena Rice Space Institute – fosters programs in all areas of space research Institute of Biosciences and Bioengineering (IBB)  – facilitates the translation of interdisciplinary research and education in biosciences and bioengineering Ken Kennedy Institute for Information Technology – dedicated to the advancement of applied interdisciplinary research in the areas of computation and information technology Baker Institute for Public Policy  – one of the leading nonpartisan public policy think tanks in the country

Students that prefer to live of-campus usually choose to live in Houston Museum District due to the wide variety of museums and easy transportation. Apartments like Alta Lofts at Herman Park, Promenade at Herman Park, The Belmont make it possible to live a luxurious life at a low cost.

Research Report of Chinese Bank IC Card Industry, 2009

To get more details, please visit www.shcri.com/reportdetail.asp?id=285 “The application of IC cards in the bankcard field is generally regarded as the inner requirements for enhancing the safety standards and service abilities of Chinese bankcards and the necessary measures to cast to the international bankcard EMV movement (from magnetic cards to smart cards ). In America, the EMV movement has been realized, the bank IC cards having substituted the magnetic cards. With the advancement of international EMV movement, the regions without IC movement will become the major targets of the counterfeit cards. Apart from the prevention of fraud risks with the counterfeit cards, the standard IC cards will support the bankcards used in the small payment areas and the fast payment areas, such as in the public transportation, convenient supermarkets and fast food industry, making the bankcards get out of the appearance limitation and realize the convenient functions like mobile phone payments. EMV is the unite technology standard of the bank chip cards for debit and credit , cooperatively made by three international credit card organizations including Europay, MasterCard and VISA. The EMV movement refers to the bankcards transformation from the magnetic cards to the integrated circuit (short for IC) cards by adopting safer and more functional smart IC cards to substitute the magnetic cards. Because the bank magnetic cards are easy to copy, swindle and steal, many countries introduce the EMV movement. At present, the EMV movement has been finished in more than 30 countries. By 2007, 67% cards (about 200 million pieces) in Europe to pay the international organizations were transferred to the smart cards suitable to the EMV standard and 67% acquirer systems had been finished the EMV standard reform. The bank associations and the credit card organizations in Middle East requested the IC cards issued after 2007 be suitable to the EMV standard. In the Asia Pacific regions, Japan and Malaysia had requested the credit cards issued after 2007 be suitable to the EMV standard. Meanwhile, the international organizations had taken different encouragement and punishment measures to propel the member banks to move towards the IC cards and the EMV direction. European MasterCard International decided that it would no longer take loss responsibilities caused by using the magnetic cards or the counterfeit cards from 2007 in Europe, which means the overall magnetic bankcards used in Europe would be replaced by the smart cards since 2007. With the acceleration of international economic communications, China is speeding up to enter international economic systems. It is the inevitable trend for Chinese bankcard industry to integrate with the international bankcard standards. By the end of 2008, China accumulatively issued 1.8-billion-piece bankcards, up by 16.7% compared with 2007, including 1.66-billion debit cards and 142-million credit cards. The growth speed of the credit cards was sharp, up by 57.7% YOY. In 2008, the bankcard businesses totaled 16.6702303 billion in China with the total amounts of 127.157376 trillion Yuan (18.17 trillion USD), up by 22.5% and 14.1% YOY respectively. It is of crucial importance to guarantee the safety of the giant amount bankcard trade. With the gradual mature of the IC card technologies, the bank IC cards have been had the basis to develop comprehensively in China. Because the smart IC cards adopt the CPU chips, which have operation, encryption and decryption and memory abilities, its safety is higher than other cards. Also, it is difficult to copy the chip cards, making the steal of the credit cards more difficult. For the application, the smart IC cards can exchange the data with the card readers by the means of encryption data communications and have strong safety authentication systems, which can cut down the possibilities of the counterfeit card crimes. EMV movement is a huge investment mainly concluding the following four parts: the costs for chip upgrade, costs for the terminal reform, costs for the mainframe system reform and spread in the issuing banks, acquirers and clearing centers and the costs for business training. At present, the manufacturing costs of each magnetic bankcard in China is about 1 Yuan (0.15 USD), but the international financial IC card costs 1 to 3 USD per piece. According to the reasonable estimation, the manufacturing costs of the domestic financial IC card is about 10 Yuan (1.46 USD) per piece. Estimated by the EMV movement of 1.8-billion bankcards on stock, the movement costs for substituting the bankcards on stock will reach to 18 billion Yuan (2.63 billion USD). The costs for single POS and ATM reform are about 2,500 Yuan (365 USD) and 8,000 Yuan (1,168 USD) respectively. The upgrade reform of these two terminals will cost 6 billion Yuan (876 million USD). According to the estimation by MasterCard International, 80% costs of the EMV movement will be applied to the upgrade and reform of the backstage and users’ training, the reform of the cards and POS terminals only accounting for 20% costs. It is predicted that the whole costs for the EMV movement in China will probably reach to 120 billion Yuan (17.5 billion USD). In consideration of the leading position of the debit cards in Chinese bankcards, comparatively low venture and the giant costs for the EMV movement, the People’s Bank of China (Chinese central banks) puts forward the gradual movement strategies of standardization first, experiments second; Foreign cards first, domestic cards second; credit first and debit second. For the standard, China Unionpay issued its own chip card standards in 2005, namely, Chinese Financial Integrated Circuit Card Regulations (PBOC2.0). For the issuance of the foreign cards, Industrial and Commercial Bank of China issued the first international credit card suitable to the EMV standard on 16th December, 2005. For the experiment places, China is now propelling the EMV movement in Shanghai and Guangzhou etc. By the end of 2008, the retain number of the credit cards in China were 142 million pieces, YOY up by 57.7%. In 2008, China new added 52-million credit cards, showing explosive growth. It is predicted that it will be the prime time in the next several years for issuing the credit cards in China (the average cards on hand per capita now is 0.1 pieces). To predict conservatively, the annual new added issuance volumes of the credit cards will be 50 million pieces. If issuing the smart cards wholly at the price of 10 Yuan (1.46 USD) per piece, the annual market capacity for the credit IC cards in China will be 500 million Yuan (73 million USD). If in accordance with the 20% issuance cards are the smart IC cards, the market capacity will be 100 million Yuan (14.6 million USD). If realizing the EMV movement in the debit cards in the future, the annual market capacity will reach to 1.5 to 3 billion Yuan (219 to 438 million USD) according to the 5 to 10 renew periods in the magnetic debit cards at present. From the time order, it is considered that the POS and ATM manufacturers will be first benefited, but it is late for the bankcard manufacturers. From the benefit level, it is considered that the bankcard manufacturers will gain more profits, because of the higher costs for the bankcard transformation. From short run, it is considered that the development of the domestic credit IC cards will be not very fast but in the trial production phase. With the completion of the acquirers with 2 years, it is imperative to spread the financial IC cards in China. ” “Table of Contents 1 Overview on Chinese Integrated Circuit Card Industry 1.1 Definition and Categories of the Integrated Circuit Cards 1.1.1 Definition and History 1.1.2 Categories 1.2 Related Policies issued by Chinese Government on the Integrated Circuit Cards 1.2.1 Related Policies 1.2.2 Supervision Systems 1.3 Standards of the Integrated Circuit Cards 1.3.1 Introduction 1.3.2 Development Trends 1.4 Chinese Integrated Circuit Card Industry Chains 1.4.1 Compositions 1.4.2 Characteristics 2 Related Product Situations of Chinese Integrated Circuit Cards 2.1 Analysis on the Integrated Circuit Card Chip Industry 2.1.1 Overview on the Market 2.1.2 Analysis on the Chip Market 2.1.3 Prediction on Chinese Chip Market 2.1.4 Introductions to the Major Chip Enterprises 2.2 Analysis on Chinese Integrated Circuit Card Market 2.2.1 Overview 2.2.2 Analysis on the Integrated Circuit Card Market 2.2.3 Competition Patterns 2.3 Analysis on Chinese IC Card Reader Industry 2.3.1 Overview on the Market 2.3.2 Analysis on IC Card Reader Market 3 Analyses on Chinese Bankcard Market 3.1 Chinese Debit Card Market 3.1.1 Development History 3.1.2 Present Situation 3.1.3 Development Trends 3.2 Chinese Quasi Credit Card Market 3.2.1 Development History 3.2.2 Present Situation 3.2.3 Development Trends 3.3 Chinese Credit Card Market 3.3.1 Development History 3.3.2 Present Situation 3.3.3 Development Trends 4 Present Technology Situations of Chinese Bankcards 4.1 Analysis on the Technology Categories of Chinese Bankcards 4.1.1 Present Technologies 4.1.2 Technical Characteristics 4.1.3 Development Trends 4.2 Scales of Chinese Bankcard Market 4.2.1 General Scale 4.2.2 Analysis and Prediction on the Scales of the Magnetic Card Market 4.2.3 Analysis and Prediction on the Scales of the Integrated Circuit Card Market 4.3 Influences of International Financial Crisis on Chinese Integrated Circuit Card Industry 4.3.1 Short Term Influences 4.4.2 Medium and Long Term Influences 5 Analyses on the EMV Movement in China 5.1 Overview on the EMV Movement in China 5.1.1 Background 5.1.2 Standards 5.1.3 Plans 5.2 Present Situation of the EMV Movement in China 5.2.1 Establishment of the International Approved EMV Test Laboratory in China 5.2.2 Establishment of the EMV Movement on Full Scale in China Unionpay 5.2.3 Research on the Smart Cards and EMV Movement by Industrial and Commercial Bank of China 5.2.4 First EMV Exchange Finished in Agricultural Bank of China 5.2.5 EMV Movement Strategies of Bank of China 5.2.6 Issuance of the Integrated Circuit Cards and EMV Movement Strategies of Construction Bank of China 5.2.7 Shanghai being the First Experiment City for EMV Movement 6 Chinese Major Integrated Circuit Card Manufacturers, 2008-2009 6.1 Beijing Zhong An Te Technologies Co. Ltd 6.1.1 Company Profiles 6.1.2 Operations 6.1.3 Development Strategies 6.2 Shanghai HuahongJt Smart Card System Co., Ltd 6.2.1 Company Profiles 6.2.2 Operations 6.2.3 Development Strategies 6.3 Zhuhai Kaijun Electronic Technology Co., Ltd 6.3.1 Company Profiles 6.3.2 Operations 6.3.3 Development Strategies 6.4 Shanghai Huaming Intelligent Terminal Equipment Co., Ltd 6.5 Beijing Huaxu Gold Card Co., Ltd 6.6 Shanghai Pujiang Smart Card Systems Co., Ltd 6.7 Shanghai Jide Electronic Equipment Co., Ltd 6.8 Beijing Yicheng Xintong Intelligent Card Technology Co., Ltd 6.9 Hunan Schlumberger Communications Equipment Co., Ltd 7 Chinese Major Issuing Banks, 2008-2009 7.1 Classification Analysis on Chinese Commercial Banks and Their Issuing Strategies 7.1.1 State-owned Commercial Banks 7.1.2 Stock Limited Commercial Banks 7.1.3 Urban Commercial Banks 7.1.4 Rural Commercial Banks 7.2 Industrial and Commercial Bank of China 7.2.1 Company Profiles 7.2.2 Development Situation of the bankcards 7.2.3 Technical Situation of the bankcards 7.2.4 Issuing Strategies 7.3 Construction Bank of China 7.3.1 Company Profiles 7.3.2 Development Situation of the bankcards 7.3.3 Technical Situation of the bankcards 7.3.4 Issuing Strategies 7.4 Agricultural Bank of China 7.4.1 Company Profiles 7.4.2 Development Situation of the bankcards 7.4.3 Technical Situation of the bankcards 7.4.4 Issuing Strategies 7.5 Bank of China 7.5.1 Company Profiles 7.5.2 Development Situation of the bankcards 7.5.3 Technical Situation of the bankcards 7.5.4 Issuing Strategies 7.6 China Merchants Bank 7.6.1 Company Profiles 7.6.2 Development Situation of the bankcards 7.6.3 Technical Situation of the bankcards 7.6.4 Issuing Strategies 7.7 Shanghai Pudong Development Bank 7.7.1 Company Profiles 7.7.2 Development Situation of the bankcards 7.7.3 Technical Situation of the bankcards 7.7.4 Issuing Strategies 7.8 Communications Bank of China 7.8.1 Company Profiles 7.8.2 Development Situation of the bankcards 7.8.3 Technical Situation of the bankcards 7.8.4 Issuing Strategies 7.9 Bank of Beijing 7.9.1 Company Profiles 7.9.2 Development Situation of the bankcards 7.9.3 Technical Situation of the bankcards 7.9.4 Issuing Strategies 8 Development and Investments in Chinese Integrated Circuit Bankcard Industry, 2009-2010 8.1 Development Environments of Chinese Integrated Circuit Bankcard Industry, 2009-2010 8.2 Investment Opportunities of Chinese Integrated Circuit Bankcard Industry, 2009-2010 8.3 Investment Ventures of Chinese Integrated Circuit Bankcard Industry, 2009-2010 8.3.1 Economic Environment Ventures 8.3.2 Technology Ventures 8.3.3 Market Ventures 8.3.4 Policy Ventures Selected Charts Chart Compositions of Chinese Integrated Circuit Card Industry Chains Chart Bankcard Issuing Volumes in China, 2001-2008 Chart Debit Card Issuing Volumes in China, 2001-2008 Chart Credit Card Issuing Volumes in China, 2001-2008 Chart Analysis and Prediction on Chinese Integrated Circuit Bankcard Issuing Volumes in China, 2008-2012 Chart Analysis and Prediction on the Integrated Circuit Bankcard Issuing Scales in Chinese Banking, 2008-2012 Chart Analysis and Prediction on the Integrated Circuit Bankcard Reader Scales in Chinese Banking, 2008-2012 Chart Debit Card Issuing Volumes by Industrial and Commercial Bank of China, 2003-2008 Chart Credit Card Issuing Volumes by Industrial and Commercial Bank of China, 2003-2008 Chart Debit Card Issuing Volumes by Construction Bank of China, 2003-2008 Chart Credit Card Issuing Volumes by Construction Bank of China, 2003-2008 Chart Credit Card Issuing Volumes by China Merchants Bank, 2003-2008 Chart Debit Card Issuing Volumes by China Merchants Bank, 2003-2008 Chart EMV Movement Routes in China Chart Exchange Volumes of the Bankcard Businesses in China, 2003-2008 Chart Exchange Amounts of the Bankcard Businesses in China, 2003-2008 ” “Table of Contents 1 Overview on the Development of Chinese Diagnostic Reagent Industry 1.1 Related Concepts of Chinese Diagnostic Reagent 1.1.1 Definition 1.1.2 Categories 1.1.3 Categories of the In Vitro Diagnostic Reagent 1.2 Development Situation of Chinese Biopharmaceuticals Industry 1.2.1 Scales 1.2.2 Development Trends 1.3 Development of Chinese Diagnostic Reagent Industry 1.3.1Market Scales 1.3.2 Present Technologies 1.3.3 Development Trends 2 Analyses on Chinese Clinical Diagnostic Reagent Industry 2.1 Overview on Chinese Clinical Diagnostic Reagent Industry 2.1.1 Development History 2.1.2 Analysis on Chinese Clinical Biochemical Diagnostic Reagent 2.1.3 Immunodiagnostics 2.1.4 Molecular Diagnostics 2.2 Present Industrialization Situation of Chinese Clinical Diagnostic Reagent 2.2.1 Overview on Chinese Clinical Diagnostic Reagent Market 2.2.2 Clinical Biochemical Diagnostic Reagent Market 2.2.3 Immunodiagnostics Market 2.2.4 Molecular Diagnostics Market 2.2.5 Other Reagent Market 2.3 Analysis on the Development of Chinese Clinical Diagnostic Reagent Industry 2.3.1 Development Perspectives 2.3.2 Challenges and Opportunities 2.4 Influences of International Financial Crisis on Chinese Clinical Diagnostic Reagent Industry 2.4.1 Short Term Influences 2.4.3 Medium and Long Term Influences 3 Present Research Situation of Chinese Diagnostic Reagent Industry 3.1 Present Situation and Development Trends of Chinese Laboratory Medicine 3.2 Research Achievements of Chinese Clinical Diagnostic Reagent Industry 3.2.1 Born of the Rapid Self-check Kits for Cervical Cancer 3.2.2 Diagnostic Technologies of Avian Influenza 3.2.3 Diagnostic Reagent for AIDS Virus 3.2.4 Rapid Immunodiagnostic Kits for Schistosomiasis 3.2.5 Diagnostic Kits for Dengue 3.2.6 Other Achievements 4 Hot Subdivisions of Chinese Diagnostic Reagent Industry 4.1 Cardiovascular Diagnostic Reagent Market 4.1.1 Analysis on the International Cardiovascular Agent Market 4.1.2 Analysis on the Outbreaks of Chinese Cardiovascular Diseases 4.1.3 Analysis on Chinese Cardiovascular System Agents 4.1.4 Analysis on Chinese Cardiovascular Diagnostic Reagent Market 4.2 Diagnostic Reagent for Sexually Transmitted Diseases 4.2.1 Analysis on the AIDS Outbreaks in the World 4.2.2 Analysis on the AIDS Outbreaks in China 4.2.3 Development Situation of Chinese AIDS Diagnostic Reagent Industry 4.3 Diagnostic Reagent for the Hepatitis 4.3.1 Analysis on the Hepatitis Outbreaks in China 4.3.2 Analysis on Chinese Hepatitis Diagnostic Reagent Market 4.4 Diagnostic Reagent for the Tumor Marks 4.4.1 Analysis on the Tumor Outbreaks in China 4.4.2 Common Tumor Marks and Major Clinical Meanings 4.4.3 Analysis on Chinese Tumor Diagnostic Reagent Market 4.5 Analysis on Chinese HTLV Diagnostic Reagent Industry 4.5.1 Brief Introduction 4.5.2 Analysis on Chinese HTLV Diagnostic Reagent Industry 5 Competition Patterns of Chinese Diagnostic Reagent Market 5.1 Competition Situation of Chinese Diagnostic Reagent Industry 5.1.1 Major Categories of the Diagnostic Reagents in China 5.1.2 Present Competition Situation of the Major Diagnostic Reagents 5.1.3 Competition Characteristics 5.1.4 Distributions of the Foreign Funded Enterprises in China 5.2 Competition Trends of Chinese Diagnostic Reagent Industry 5.2.1 Merger and Acquisition Trends 5.2.2 Prediction on the Distributions of the Foreign Funded Enterprises in China 6 Major Foreign Funded Enterprises of Chinese Diagnostic Reagent Industry 6.1 Roche Group 6.1.1 Company Profiles 6.1.2 Operations in China 6.1.3 Development Strategies 6.2 Johnson & Johnson Services, Inc 6.2.1 Company Profiles 6.2.2 Operations in China 6.2.3Development Strategies 6.3 GlaxoSmithKline 6.3.1 Company Profiles 6.3.2 Operations in China 6.3.3 Development Strategies 6.4 Pfizer Limited 6.5 Abbott Laboratories 7 Major Local Enterprises of Chinese Diagnostic Reagent Industry 7.1 Shanghai Fosun Pharmaceutical (Group) Co., Ltd 7.1.1 Company Profiles 7.1.2 Major Diagnostic Reagent Products 7.1.3 Development Strategies 7.2 Shanghai Kehua Bio-engineering Co., Ltd 7.2.1 Company Profiles 7.2.2 Major Diagnostic Reagent Products 7.2.3 Development Strategies 7.3 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd 7.3.1 Company Profiles 7.3.2 Major Diagnostic Reagent Products 7.3.3 Development Strategies 7.4 Shanghai Rongsheng Biotech Co., Ltd 7.5 Nanjing Jiancheng Bioengineering Institute 7.6 Livzon Pharmaceutical Group Inc. 7.7 Huamei Bioengineering Co., Ltd 7.8 Huasin Science Co., Ltd 7.9 DaAn Gene Co., Ltd 8 Development Strategies to Entry Chinese Diagnostic Reagent Market 8.1 Investment Problems in Chinese Biopharmaceuticals Industry 8.2 Product Strategies of Chinese Diagnostic Reagent Enterprises 8.3 Competition Strategies of Chinese Diagnostic Reagent Enterprises 8.4 Development Strategies of Chinese Diagnostic Reagent Industry 8.5 Comparisons of the Marketing Strategies between Chinese and Foreign Diagnostic Reagent Enterprises 8.5.1 Strategies of the Product Orientation 8.5.2 Strategies of the Product Price Making 8.5.3 Comparisons of the Distribution Channels 9 Development Trends of Chinese Diagnostic Reagent Industry 9.1 Development Trends of Chinese Pharmaceuticals Industry 9.1.1 Prediction on the Market Scales 9.1.2 Prediction on the Market Structures 9.1.3 Prediction on the Development of Chinese Biopharmaceuticals Industry 9.2 Development Perspectives of Chinese Diagnostic Reagent Industry 9.2.1 SWOF Analysis on the Development 9.2.2 Prediction on the Scales 9.2.3 Prediction on the Technologies 9.3 Prediction on the Development and Investments of Chinese Diagnostic Reagent Industry Selected Charts Chart Analysis on Chinese Diagnostic Reagent Products Chart Scales of Chinese Diagnostic Reagent Market, 2004-2008 Chart Outbreak and Mortality Rates of Chinese Major Infectious Diseases, 2008 Chart Purchase Amounts of the Anti-tumor Drugs in Chinese Hospitals, 2004-2008 Chart Fierce Competitions among the Anti-tumor Products and Immunomodulator Products in China Chart Quantity Sheet of Chinese Approved Anti-tumor Drugs and Immunomodulator Products in Class A and B Chart Categories and Technologies of POCT Chart Synopsis of the Major Diagnostic Reagent Varieties and the Manufacturers in China Chart Operations of Shanghai Kehua Bio-engineering Co., Ltd, 2004-2008 ”

Research Report of Chinese Diagnostic Reagent Industry, 2009

The development of Chinese laboratory medicine fell far behind the world’s advanced level for a long time. In the 1970s, China still continued to use the methods in the 1950s, namely, the various necessary diagnostics reagents were self-prepared by the technicians. In the 1970s, China began to introduce some foreign advanced equipments and technologies. Since the 1980s, Chinese clinical diagnostic reagent industry had quickly step into the industrialization process with the introduction of the foreign capitals.

 To get more details, please visit http://www.shcri.com/reportdetail.asp?id=286

In 2008, the scale of Chinese diagnostic reagent market was about 600 million USD with the growth speed of 15 to 20 percent in recent years.

 

Generally speaking, the widely clinically applied and vast market technologies of Chinese major enterprises have achieved the international level of the same period, including the immunodiagnostics of hepatitis, sexually transmitted diseases and fertility test and the enzymes, Lipids, liver function, blood sugar and urinalysis series in the clinical biochemical. The PCR technology for the genetic test had reached to the international advanced level; the technologies of DNA Chips and tumor series are running to catch up the international level.

 

Due to the market and policy factors and the backward application technologies of domestic electromechanical integration, some projects in the microbiology are developed slowly in low technologies.

 

The biggest perplex of Chinese diagnostic reagent industry is the repeated appearance of the same kind products in inferior quality, affecting the healthy development of the whole industry. These projects are derived from the domestic researches or imported abroad by various channels but without real creativity.

 

At present, there are hundreds of diagnostic technology enterprises in various sizes, but the scale is limited and some are even in the laboratory phase. The diagnostic enterprises, as a new biological hi-tech enterprises, start late in China. Compared with the multinational enterprises, the domestic enterprises are in small scales, few varieties and in disparate development. Many enterprises invest huge research capitals in the former period, leading to the meaning losses because of the long exploitation period and fast market changes.

 

The mergers in Chinese diagnostic reagent industry have been on, in which the small enterprises will be replaced and the large enterprises will be grown in strength.

 

From the present situation, the diagnostic reagent industry and the equipment industry are under developed in local Chinese enterprises, forming the patterns that the equipments can’t match with the reagents. Compared with foreign companies, the biggest disadvantage of the local enterprises is the brand, because the foreign funded enterprises have long histories, the consumers prefer to choose the foreign brands. The advantages of the local enterprises lie in the familiarity with the local market demands and price competitiveness. At present, these enterprises enable to cover or solve the problems in the second class hospitals. Although there is no problem in covering the third class hospitals, the make-up in the automation systems, data processing and the general industrialization level are behind the foreign technologies.

 

Although in its beginning phase, the high profit return attracts many investors to enter Chinese diagnostic reagent industry. On 5th June, 2007, the first multinational capital import was succeeded in the field of Chinese diagnostic reagents. Beijing Chemclin Biotech Co., Ltd, provider of the diagnostic reagents and equipments, announced the first round obtainment of 5-million-USD venture investments, dominated by WI Harper Group and Siemens Venture Capital and participated by SB China Venture Capital.

 

The profit return of the diagnostic reagents is very high. The overall investments in a new diagnostic reagent can be recovered after the public in 2 to 3 years, especially the enterprises with new products or patented products. Once the products exploitation is successful, the technologies will be monopolized with the profit return exceeding 10 folds or more.

 

Chinese medical reforms had been started since the latter half of 2008. The key point of the medical reforms was to develop towards the medium and low market, request the diagnostics and prevention to be more accurate so as to cut down the costs and improve the medical treatment efficiency. This was a big market and only the products with low costs could meet the demands. In the Major Recent Implementation Plans of Chinese Pharmaceuticals and Hygienic System Reform (2009 to 2010), the intensification in the basic public hygiene services will drive the sharp sales growth of the diagnostic reagent products, pointing out the control and prevention and national immunity plans against the big epidemics, such as T.B. and AIDS. It is predicted that the basic public hygiene services will propel the sales growth of Chinese common diagnostic preparation.   

 

From the medically clinical experiences in the developed countries, the diagnostic costs account for 20 to 30 percent of the whole medical costs, but which is less than 10% in China. Therefore, great market space has been not exploited so far.

 

“Table of Contents
1 Overview on the Development of Chinese Diagnostic Reagent Industry
1.1 Related Concepts of Chinese Diagnostic Reagent
1.1.1 Definition
1.1.2 Categories
1.1.3 Categories of the In Vitro Diagnostic Reagent
1.2 Development Situation of Chinese Biopharmaceuticals Industry
1.2.1 Scales 
1.2.2 Development Trends
1.3 Development of Chinese Diagnostic Reagent Industry
1.3.1Market Scales
1.3.2 Present Technologies
1.3.3 Development Trends

2 Analyses on Chinese Clinical Diagnostic Reagent Industry
2.1 Overview on Chinese Clinical Diagnostic Reagent Industry
2.1.1 Development History 
2.1.2 Analysis on Chinese Clinical Biochemical Diagnostic Reagent
2.1.3 Immunodiagnostics
2.1.4 Molecular Diagnostics
2.2 Present Industrialization Situation of Chinese Clinical Diagnostic Reagent
2.2.1 Overview on Chinese Clinical Diagnostic Reagent Market
2.2.2 Clinical Biochemical Diagnostic Reagent Market
2.2.3 Immunodiagnostics Market
2.2.4 Molecular Diagnostics Market
2.2.5 Other Reagent Market
2.3 Analysis on the Development of Chinese Clinical Diagnostic Reagent Industry
2.3.1 Development Perspectives
2.3.2 Challenges and Opportunities 
2.4 Influences of International Financial Crisis on Chinese Clinical Diagnostic Reagent Industry
2.4.1 Short Term Influences
2.4.3 Medium and Long Term Influences

3 Present Research Situation of Chinese Diagnostic Reagent Industry
3.1 Present Situation and Development Trends of Chinese Laboratory Medicine
3.2 Research Achievements of Chinese Clinical Diagnostic Reagent Industry
3.2.1 Born of the Rapid Self-check Kits for Cervical Cancer
3.2.2 Diagnostic Technologies of Avian Influenza 
3.2.3 Diagnostic Reagent for AIDS Virus 
3.2.4 Rapid Immunodiagnostic Kits for Schistosomiasis
3.2.5 Diagnostic Kits for Dengue
3.2.6 Other Achievements

4 Hot Subdivisions of Chinese Diagnostic Reagent Industry
4.1 Cardiovascular Diagnostic Reagent Market
4.1.1 Analysis on the International Cardiovascular Agent Market
4.1.2 Analysis on the Outbreaks of Chinese Cardiovascular Diseases
4.1.3 Analysis on Chinese Cardiovascular System Agents
4.1.4 Analysis on Chinese Cardiovascular Diagnostic Reagent Market
4.2 Diagnostic Reagent for Sexually Transmitted Diseases 
4.2.1 Analysis on the AIDS Outbreaks in the World
4.2.2 Analysis on the AIDS Outbreaks in China 
4.2.3 Development Situation of Chinese AIDS Diagnostic Reagent Industry
4.3 Diagnostic Reagent for the Hepatitis
4.3.1 Analysis on the Hepatitis Outbreaks in China
4.3.2 Analysis on Chinese Hepatitis Diagnostic Reagent Market
4.4 Diagnostic Reagent for the Tumor Marks 
4.4.1 Analysis on the Tumor Outbreaks in China
4.4.2 Common Tumor Marks and Major Clinical Meanings
4.4.3 Analysis on Chinese Tumor Diagnostic Reagent Market
4.5 Analysis on Chinese HTLV Diagnostic Reagent Industry
4.5.1 Brief Introduction 
4.5.2 Analysis on Chinese HTLV Diagnostic Reagent Industry

5 Competition Patterns of Chinese Diagnostic Reagent Market 
5.1 Competition Situation of Chinese Diagnostic Reagent Industry
5.1.1 Major Categories of the Diagnostic Reagents in China
5.1.2 Present Competition Situation of the Major Diagnostic Reagents
5.1.3 Competition Characteristics
5.1.4 Distributions of the Foreign Funded Enterprises in China
5.2 Competition Trends of Chinese Diagnostic Reagent Industry
5.2.1 Merger and Acquisition Trends
5.2.2 Prediction on the Distributions of the Foreign Funded Enterprises in China

6 Major Foreign Funded Enterprises of Chinese Diagnostic Reagent Industry
6.1 Roche Group
6.1.1 Company Profiles
6.1.2 Operations in China
6.1.3 Development Strategies
6.2 Johnson & Johnson Services, Inc
6.2.1 Company Profiles
6.2.2 Operations in China
6.2.3Development Strategies
6.3 GlaxoSmithKline
6.3.1 Company Profiles
6.3.2 Operations in China
6.3.3 Development Strategies
6.4 Pfizer Limited
6.5 Abbott Laboratories

7 Major Local Enterprises of Chinese Diagnostic Reagent Industry
7.1 Shanghai Fosun Pharmaceutical (Group) Co., Ltd
7.1.1 Company Profiles
7.1.2 Major Diagnostic Reagent Products
7.1.3 Development Strategies
7.2 Shanghai Kehua Bio-engineering Co., Ltd
7.2.1 Company Profiles
7.2.2 Major Diagnostic Reagent Products
7.2.3 Development Strategies
7.3 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd
7.3.1 Company Profiles
7.3.2 Major Diagnostic Reagent Products
7.3.3 Development Strategies
7.4 Shanghai Rongsheng Biotech Co., Ltd
7.5 Nanjing Jiancheng Bioengineering Institute
7.6 Livzon Pharmaceutical Group Inc.
7.7 Huamei Bioengineering Co., Ltd
7.8 Huasin Science Co., Ltd
7.9 DaAn Gene Co., Ltd

8 Development Strategies to Entry Chinese Diagnostic Reagent Market 
8.1 Investment Problems in Chinese Biopharmaceuticals Industry
8.2 Product Strategies of Chinese Diagnostic Reagent Enterprises
8.3 Competition Strategies of Chinese Diagnostic Reagent Enterprises
8.4 Development Strategies of Chinese Diagnostic Reagent Industry
8.5 Comparisons of the Marketing Strategies between Chinese and Foreign Diagnostic Reagent Enterprises
8.5.1 Strategies of the Product Orientation
8.5.2 Strategies of the Product Price Making
8.5.3 Comparisons of the Distribution Channels

9 Development Trends of Chinese Diagnostic Reagent Industry
9.1 Development Trends of Chinese Pharmaceuticals Industry 
9.1.1 Prediction on the Market Scales
9.1.2 Prediction on the Market Structures
9.1.3 Prediction on the Development of Chinese Biopharmaceuticals Industry
9.2 Development Perspectives of Chinese Diagnostic Reagent Industry
9.2.1 SWOF Analysis on the Development
9.2.2 Prediction on the Scales
9.2.3 Prediction on the Technologies
9.3 Prediction on the Development and Investments of Chinese Diagnostic Reagent Industry

Selected Charts
Chart Analysis on Chinese Diagnostic Reagent Products
Chart Scales of Chinese Diagnostic Reagent Market, 2004-2008
Chart Outbreak and Mortality Rates of Chinese Major Infectious Diseases, 2008
Chart Purchase Amounts of the Anti-tumor Drugs in Chinese Hospitals, 2004-2008
Chart Fierce Competitions among the Anti-tumor Products and Immunomodulator Products in China
Chart Quantity Sheet of Chinese Approved Anti-tumor Drugs and Immunomodulator Products in Class A and B
Chart Categories and Technologies of POCT
Chart Synopsis of the Major Diagnostic Reagent Varieties and the Manufacturers in China  
Chart Operations of Shanghai Kehua Bio-engineering Co., Ltd, 2004-2008
“

Eggs Benifits for Health

Omega 3 eggs are good for our health since they are enriched. It means they contain fatty acids in just the right quantities as needed by our body on a daily basis. In addition to this, these eggs also contain vitamin E, an antioxidant.

These eggs taste just like regular eggs and also have a real egg shell. They can be used in making different dishes including baked desserts and all kinds of tasty recipes. They are good for people with high blood pressure and high cholesterol. Omega 3 fatty acids reduce inflammation throughout the body and also make the heart stronger and healthier.

Omega 3 eggs are an excellent alternative for those who don’t like the taste of fish oil. They can easily consume these eggs by mixing them with other food materials on a regular basis. If you include good quality nutritional supplements in your everyday diet along with omega 3 enriched eggs, all your nutritional needs for omega 3 fats will be fulfilled.

These eggs are actually produced by feeding some special foods to the hens. Normally up to 300 mg of omega 3 fatty acid content is found in these eggs which is enough to fulfill a day’s requirements. It’s also important to know that an oily fish if eaten with bones provides up to 1000 mg of omega 3. You may want to consult a dietary chart to determine the exact amount of omega 3’s you need on a daily basis.

Other sources include flax seed oil and soybeans and are recommended to be consumed in their raw form since heat damages their omega 3 content. However, eggs can be cooked, baked or heated otherwise before using. It retains their omega content and provides equal benefits either way.

If you are looking for supplements online, find the ones made with pharmaceutical grade fish oil. These supplement products are effective and 3 to 4 fish oil capsules are enough to fulfill a day’s needs. 300 to 400 mg of DHA and EPA combined are normally advised by doctors and health specialists all over the world.

Eggs and fish oil capsules are good for people of all ages. Those who are deficient and those who are not, both can obtain unlimited benefits by consuming omega 3 enriched foods regularly.

The egg source in your diet makes a difference because bioengineered… man-made corn is fed to typical chickens. It looks that poultry is sicker than person who eats them.

Bioengineered Eggs vs. Organic Eggs

Brain washing against eggs is so intense, that we keep forgetting how perfect ORGANIC eggs are… Well guess what… even more perfect are the fertile eggs.

You’ll get everything you need and the list is long… Vitamins, Minerals, Amino Acids and Protein to name just a few… all in perfect balance.

Eggs are the winners but… the negative publicity over the years did lot damage to the ‘eggs image’ and the result is devastating… More and more people are buying cereals… they turned to the competition.

Calcium concentration must be kept constant, and if not enough is taken in to the body, calcium will be withdrawn from the store sites in your bones. The bones will gradually become less dense, losing some of their strength, which can then lead to osteoporosis (brittle, porous bones). Withdrawing calcium from the bones is the body’s way of keeping blood levels constant.

Read About Fast Weight Loss Also Read About Salad Diet and Eggs to Lose Weight